经股动脉与经肱动脉或经桡动脉入路行颈动脉支架置入术的结局比较
基于血管质量倡议(VQI)数据库2012年1月至2021年6月23965例非经颈动脉血运重建的颈动脉支架置入术患者,比较经股动脉(TF)与经肱/桡动脉(TR/TB)入路的结局。
核心结论
- 本研究证实,尽管TR或TB入路在技术上更具挑战性,但作为颈动脉支架置入术的合理替代方案,其入路部位并发症较低,尤其适用于解剖因素妨碍经股动脉颈动脉支架置入术或经颈动脉血运重建的患者。
- 然而,TR/TB入路与技术失败和心肌梗死风险增加相关,需进一步研究。
研究设计与样本
- 回顾性队列研究,纳入血管质量倡议(VQI)数据库2012年1月至2021年6月所有接受非经颈动脉血运重建的颈动脉支架置入术患者。
- 共纳入23965例患者,按入路分为经股动脉(TF)组23146例(96.6%)和经肱/桡动脉(TR/TB)组819例(3.4%)。
- 采用单因素和多因素逻辑回归模型评估术后结局,并校正年龄、性别、种族、狭窄程度、症状状态、麻醉方式、合并症和术前药物等相关潜在混杂因素。
主要发现
- TR/TB组男性比例高于TF组(69.4% vs 64.9%,P=0.009),症状性患者比例高于TF组(49.9% vs 28.6%,P<0.001)。
- TR/TB组术前 guideline directed medications 使用率高于TF组:P2Y12抑制剂(80.3% vs 74.7%,P<0.01)、他汀(83.8% vs 80.6%)、阿司匹林(88.3% vs 84.5%,P=0.003)。
临床怎么用
- 作者认为,TR或TB入路可作为颈动脉支架置入术的合理替代方案,尤其适用于解剖因素妨碍经股动脉颈动脉支架置入术或经颈动脉血运重建的患者,其入路部位并发症较低。
- 作者指出,TR/TB入路与技术失败和心肌梗死风险增加相关,需进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While Transfemoral Carotid Artery Stenting (TFCAS) is a valid minimally invasive option for patients who also might be suitable for carotid endarterectomy (CEA) or transcarotid artery revascularization (TCAR), alternative access sites such as transbrachial (TB) or transradial (TR) are only utilized when anatomic factors preclude direct carotid or transfemoral access. In this study, we aimed to evaluate the outcomes of TR/TB access in comparison to TF for percutaneous carotid artery revascularization. METHODS: All patients undergoing non-TCAR carotid artery stenting (CAS) from January 2012 to June 2021 in the Vascular Quality Initiative (VQI) Database were included. Patients were divided into 2 groups based on the access site for CAS: TF or TR/TB. Primary outcomes included stroke/death, technical failure and access site complications (hematoma, stenosis, infection, pseudoaneurysm and AV fistula). Secondary outcomes included stroke, TIA, MI, death, non-home discharge, extended length of postoperative stay (LOS) (>1 day), and composite endpoints of stroke/MI and stroke/death/MI. Univariable and multivariable logistic regression models were used to assess postoperative outcomes, and results were adjusted for relevant potential confounders including age, gender, race, degree of stenosis, symptomatic status, anesthesia, comorbidities, and preoperative medications. RESULTS: Out of the 23,965 patients, TR/TB approach was employed in 819 (3.4%) while TF was used in 23,146 (96.6%). Baseline characteristics found men were more likely to undergo revascularization using TR/TB approach (69.4% vs. 64.9%, P = 0.009). Patients undergoing TR/TB approach were also more likely to be symptomatic (49.9% vs. 28.6%, P < 0.001). Guideline directed medications were more frequently used with TR/TB including P2Y12 inhibitor (80.3% vs. 74.7%, P < 0.01), statin (83.8% vs. 80.6%), and aspirin (88.3% vs. 84.5%, P = 0.003) preoperatively. On univariate analysis, patients with TB/TR approach experienced higher rates of adverse outcomes. After adjusting for potential confounders, TR/TB patients had no significant increase in the risk of stroke/death [aOR 1.10 (0.69-1.76), P = 0.675]; however, the use of TR/TB access was associated with a more than 2-fold increase in risk for in-hospital MI [aOR 2.39 (1.32-4.30), P = 0.004] and 2-fold increase in risk of technical failure [aOR 2.21 (1.31-3.73) P = 0.003]. The use of TR/TB access was also associated with a 50% reduction in the risk of access site complications [aOR 0.53 (0.32-0.85), P = 0.009]. CONCLUSIONS: This study confirms that although technically more challenging, TR or TB approach serves as a reasonable alternative with lower access site complications for CAS particularly in patients where anatomic factors preclude revascularization by TFCAS or TCAR. However, TR/TB is associated with an increased risk of technical failure and myocardial infarction, which requires further study.
引用
- Khan MA, Dodo-Williams TS, Janssen C, et al. Comparing Outcomes of Transfemoral Versus Transbrachial or Transradial Approach in Carotid Artery Stenting (CAS). Ann Vasc Surg. 2023. PMID: 36758939. doi:10.1016/j.avsg.2023.01.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。